Alpha Cognition (NASDAQ:ACOG – Get Free Report) and Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.
Volatility & Risk
Alpha Cognition has a beta of 2.32, meaning that its share price is 132% more volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.
Profitability
This table compares Alpha Cognition and Collegium Pharmaceutical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Alpha Cognition | -153.61% | -54.60% | -43.47% |
| Collegium Pharmaceutical | 4.68% | 85.14% | 13.80% |
Earnings and Valuation
This table compares Alpha Cognition and Collegium Pharmaceutical”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alpha Cognition | $10.22 million | 17.67 | -$20.67 million | ($1.10) | -7.54 |
| Collegium Pharmaceutical | $780.57 million | 1.01 | $62.87 million | $1.00 | 24.21 |
Collegium Pharmaceutical has higher revenue and earnings than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Alpha Cognition and Collegium Pharmaceutical, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alpha Cognition | 0 | 0 | 5 | 0 | 3.00 |
| Collegium Pharmaceutical | 1 | 1 | 7 | 1 | 2.80 |
Alpha Cognition presently has a consensus target price of $18.00, suggesting a potential upside of 117.13%. Collegium Pharmaceutical has a consensus target price of $44.88, suggesting a potential upside of 85.36%. Given Alpha Cognition’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Alpha Cognition is more favorable than Collegium Pharmaceutical.
Summary
Collegium Pharmaceutical beats Alpha Cognition on 8 of the 12 factors compared between the two stocks.
About Alpha Cognition
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.
